Basic Information
| LncRNA/CircRNA Name | WDFY3-AS2 |
| Synonyms | NA |
| Region | GRCh38_4:84965682-85011277 |
| Ensemble | ENSG00000180769 |
| Refseq | NR_015359 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP |
| Sample | Human OC cell lines A2780, CP70, SKOV3, CAOV3, and normal ovarian epithelial cell line IOSE80, OC and adjacent tissue |
| Expression Pattern | down-regulated |
| Function Description | WDFY3-AS2 and RORA were underexpressed in OC, while miR-18a was highly expressed. Notably, WDFY3-AS2 acts as a competing endogenous RNA to sponge miR-18a and upregulate RORA. Upon overexpressing WDFY3-AS2 or inhibiting miR-18a, RORA expression was increased, thereby the OC cell proliferation, migration, invasion, and epithelial-to-mesenchymal transition (EMT) were suppressed, accompanied by enhanced apoptosis. In vivo experiments confirmed that the tumor growth was reduced in response to overexpressed WDFY3-AS2 or inhibited miR-18a. |
| Pubmed ID | 31347170 |
| Year | 2019 |
| Title | Long noncoding RNA WDFY3-AS2 suppresses tumor progression by acting as a competing endogenous RNA of microRNA-18a in ovarian cancer |
External Links
| Links for WDFY3-AS2 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |